ACELRX PHARMACEUT. DL-01 (R5XA) - Total Liabilities
Based on the latest financial reports, ACELRX PHARMACEUT. DL-01 (R5XA) has total liabilities worth €12.68 Million EUR (≈ $14.83 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does ACELRX PHARMACEUT. DL-01 generate cash to assess how effectively this company generates cash.
ACELRX PHARMACEUT. DL-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how ACELRX PHARMACEUT. DL-01's total liabilities have evolved over time, based on quarterly financial data. Check R5XA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
ACELRX PHARMACEUT. DL-01 Competitors by Total Liabilities
The table below lists competitors of ACELRX PHARMACEUT. DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eightco Holdings Inc.
NASDAQ:OCTO
|
USA | $40.18 Million |
|
Wesizwe
JSE:WEZ
|
South Africa | ZAC30.29 Billion |
|
Total Soft Bank Ltd
KQ:045340
|
Korea | ₩19.09 Billion |
|
Webus International Limited Ordinary Shares
NASDAQ:WETO
|
USA | $27.44 Million |
|
Skyline Builders Group Holding Limited Class A Ordinary Shares
NASDAQ:SKBL
|
USA | $2.56 Million |
|
Hung Chou Fiber Ind Co Ltd
TW:1413
|
Taiwan | NT$1.30 Billion |
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
USA | $11.50 Million |
|
RS GROUP PLC
LSE:RS1
|
UK | GBX1.27 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ACELRX PHARMACEUT. DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see R5XA market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACELRX PHARMACEUT. DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACELRX PHARMACEUT. DL-01 (2021–2025)
The table below shows the annual total liabilities of ACELRX PHARMACEUT. DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €12.68 Million ≈ $14.83 Million |
+23.93% |
| 2024-12-31 | €10.23 Million ≈ $11.97 Million |
+62.72% |
| 2023-12-31 | €6.29 Million ≈ $7.35 Million |
-75.50% |
| 2022-12-31 | €25.67 Million ≈ $30.01 Million |
-77.44% |
| 2021-12-31 | €113.79 Million ≈ $133.03 Million |
-- |
About ACELRX PHARMACEUT. DL-01
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat… Read more